Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($)
$ in Thousands |
Clyra Medical Technologies [Member]
Common Stock [Member]
|
Clyra Medical Technologies [Member]
Additional Paid-in Capital [Member]
|
Clyra Medical Technologies [Member]
Retained Earnings [Member]
|
Clyra Medical Technologies [Member]
AOCI Attributable to Parent [Member]
|
Clyra Medical Technologies [Member]
Noncontrolling Interest [Member]
|
Clyra Medical Technologies [Member] |
BioLargo Energy Technologies, Inc (BETI) [Member]
Common Stock [Member]
|
BioLargo Energy Technologies, Inc (BETI) [Member]
Additional Paid-in Capital [Member]
|
BioLargo Energy Technologies, Inc (BETI) [Member]
Retained Earnings [Member]
|
BioLargo Energy Technologies, Inc (BETI) [Member]
AOCI Attributable to Parent [Member]
|
BioLargo Energy Technologies, Inc (BETI) [Member]
Noncontrolling Interest [Member]
|
BioLargo Energy Technologies, Inc (BETI) [Member] |
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Retained Earnings [Member] |
AOCI Attributable to Parent [Member] |
Noncontrolling Interest [Member] |
Total |
| Balance (in shares) at Dec. 31, 2024 |
|
|
|
|
|
|
|
|
|
|
|
|
301,274,243
|
|
|
|
|
|
| Balance at Dec. 31, 2024 |
|
|
|
|
|
|
|
|
|
|
|
|
$ 202
|
$ 158,332
|
$ (149,500)
|
$ (183)
|
$ (2,795)
|
$ 6,056
|
| Sale of common stock for cash (unaudited) (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
| Issuance of common stock for services (unaudited) (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
220,330
|
|
|
|
|
|
| Issuance of common stock for services (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
61
|
0
|
0
|
0
|
61
|
| Stock option compensation expense (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
409
|
0
|
0
|
0
|
409
|
| Clyra Medical stock option compensation expense (unaudited) |
$ 0
|
$ 0
|
$ 0
|
$ 0
|
$ 206
|
$ 206
|
|
|
|
|
|
|
|
|
|
|
|
|
| Clyra Medical dividend Series A Preferred stock (unaudited) |
0
|
0
|
0
|
0
|
(86)
|
(86)
|
|
|
|
|
|
|
|
|
|
|
|
|
| Clyra Medical fair value warrant issued with debt (unaudited) |
0
|
0
|
0
|
0
|
69
|
69
|
|
|
|
|
|
|
|
|
|
|
|
|
| Noncontrolling interest allocation (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
(522)
|
0
|
0
|
522
|
0
|
| Net loss (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
(1,155)
|
0
|
(766)
|
(1,921)
|
| Foreign currency translation (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
0
|
0
|
(20)
|
0
|
(20)
|
| Clyra Medical stock issued for services (unaudited) |
0
|
0
|
0
|
0
|
36
|
36
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance (in shares) at Mar. 31, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
301,760,373
|
|
|
|
|
|
| Balance at Mar. 31, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
$ 202
|
158,265
|
(150,655)
|
(203)
|
(2,519)
|
5,090
|
| Sale of common stock for cash, net of offering costs of $15 (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
(15)
|
0
|
0
|
0
|
(15)
|
| Stock option exercise (unaudited) (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
265,800
|
|
|
|
|
|
| Stock option exercise (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
0
|
0
|
0
|
0
|
0
|
| Clyra Medical stock unit offering (unaudited) |
0
|
0
|
0
|
0
|
295
|
295
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock for cash, net offering costs of $15 (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
(15)
|
0
|
0
|
0
|
(15)
|
| Balance (in shares) at Dec. 31, 2024 |
|
|
|
|
|
|
|
|
|
|
|
|
301,274,243
|
|
|
|
|
|
| Balance at Dec. 31, 2024 |
|
|
|
|
|
|
|
|
|
|
|
|
$ 202
|
158,332
|
(149,500)
|
(183)
|
(2,795)
|
6,056
|
| Foreign currency translation (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(20)
|
| Balance (in shares) at Jun. 30, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
306,752,661
|
|
|
|
|
|
| Balance at Jun. 30, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
$ 205
|
160,601
|
(151,848)
|
(203)
|
(2,695)
|
6,060
|
| Balance (in shares) at Mar. 31, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
301,760,373
|
|
|
|
|
|
| Balance at Mar. 31, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
$ 202
|
158,265
|
(150,655)
|
(203)
|
(2,519)
|
5,090
|
| Sale of common stock for cash (unaudited) (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
4,077,285
|
|
|
|
|
|
| Issuance of common stock for services (unaudited) (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
915,003
|
|
|
|
|
|
| Issuance of common stock for services (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
212
|
0
|
0
|
0
|
212
|
| Stock option compensation expense (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
292
|
0
|
0
|
0
|
292
|
| Clyra Medical stock option compensation expense (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
0
|
200
|
200
|
| Clyra Medical dividend Series A Preferred stock (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
0
|
(86)
|
(86)
|
| Clyra Medical fair value warrant issued with debt (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
0
|
93
|
93
|
| Noncontrolling interest allocation (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
1,027
|
0
|
0
|
(1,027)
|
0
|
| Net loss (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
(1,193)
|
0
|
(689)
|
(1,882)
|
| Foreign currency translation (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
| Clyra Medical stock issued for services (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
0
|
0
|
0
|
24
|
24
|
| Balance (in shares) at Jun. 30, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
306,752,661
|
|
|
|
|
|
| Balance at Jun. 30, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
$ 205
|
160,601
|
(151,848)
|
(203)
|
(2,695)
|
6,060
|
| Sale of common stock for cash, net of offering costs of $15 (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
3
|
805
|
0
|
0
|
0
|
808
|
| Sale of stock for cash, net offering costs of $15 (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
3
|
805
|
0
|
0
|
0
|
808
|
| Clyra Medical Unit Warrant offering (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
0
|
0
|
0
|
1,309
|
1,309
|
| Balance (in shares) at Dec. 31, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
317,377,777
|
|
|
|
|
|
| Balance at Dec. 31, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
$ 213
|
165,316
|
(161,280)
|
(207)
|
(2,516)
|
1,526
|
| Sale of common stock for cash (unaudited) (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
1,539,744
|
|
|
|
|
|
| Sale of common stock for cash (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 1
|
255
|
0
|
0
|
0
|
256
|
| Issuance of common stock for services (unaudited) (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
282,407
|
|
|
|
|
|
| Issuance of common stock for services (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
46
|
0
|
0
|
0
|
46
|
| Stock option compensation expense (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
286
|
0
|
0
|
0
|
286
|
| Common stock issued as a fee (unaudited) (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
500,000
|
|
|
|
|
|
| Common stock issued as a fee (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
85
|
0
|
0
|
0
|
85
|
| Clyra Medical stock option compensation expense (unaudited) |
0
|
0
|
0
|
0
|
413
|
413
|
|
|
|
|
|
|
|
|
|
|
|
|
| Clyra Medical dividend Series A Preferred stock (unaudited) |
0
|
0
|
0
|
0
|
(86)
|
(86)
|
|
|
|
|
|
|
|
|
|
|
|
|
| Clyra Medical fair value warrant issued with debt (unaudited) |
$ 0
|
$ 0
|
$ 0
|
$ 0
|
$ 232
|
$ 232
|
|
|
|
|
|
|
|
|
|
|
|
|
| BETI unit offering (unaudited) |
|
|
|
|
|
|
$ 0
|
$ 0
|
$ 0
|
$ 0
|
$ 462
|
$ 462
|
|
|
|
|
|
|
| Noncontrolling interest allocation (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
(641)
|
0
|
0
|
641
|
0
|
| Net loss (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
(2,286)
|
0
|
(1,119)
|
(3,405)
|
| Foreign currency translation (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
0
|
0
|
(2)
|
0
|
(2)
|
| Balance (in shares) at Mar. 31, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
319,699,928
|
|
|
|
|
|
| Balance at Mar. 31, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
$ 214
|
165,347
|
(163,566)
|
(209)
|
(1,973)
|
(187)
|
| Balance (in shares) at Dec. 31, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
317,377,777
|
|
|
|
|
|
| Balance at Dec. 31, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
$ 213
|
165,316
|
(161,280)
|
(207)
|
(2,516)
|
1,526
|
| Foreign currency translation (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
| Balance (in shares) at Jun. 30, 2026 |
|
|
|
|
|
|
|
|
|
|
|
9,738,469
|
325,231,362
|
|
|
|
|
|
| Balance at Jun. 30, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
$ 217
|
164,470
|
(166,333)
|
(206)
|
(878)
|
(2,730)
|
| Balance (in shares) at Mar. 31, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
319,699,928
|
|
|
|
|
|
| Balance at Mar. 31, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
$ 214
|
165,347
|
(163,566)
|
(209)
|
(1,973)
|
(187)
|
| Sale of common stock for cash (unaudited) (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
3,250,000
|
|
|
|
|
|
| Sale of common stock for cash (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 2
|
389
|
0
|
0
|
0
|
391
|
| Issuance of common stock for services (unaudited) (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
2,281,434
|
|
|
|
|
|
| Issuance of common stock for services (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 1
|
235
|
0
|
0
|
0
|
236
|
| Stock option compensation expense (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
472
|
0
|
0
|
0
|
472
|
| Clyra Medical stock option compensation expense (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
0
|
250
|
250
|
| Clyra Medical dividend Series A Preferred stock (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
0
|
(87)
|
(87)
|
| Clyra Medical fair value warrant issued with debt (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
0
|
121
|
121
|
| BETI unit offering (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
0
|
25
|
25
|
| Noncontrolling interest allocation (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
(1,973)
|
0
|
0
|
1,973
|
0
|
| Net loss (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
(2,767)
|
0
|
(1,233)
|
(4,000)
|
| Foreign currency translation (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
3
|
0
|
3
|
| Clyra Medical stock issued for services (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
0
|
17
|
17
|
| Clyra Medical stock option exercise (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
0
|
5
|
5
|
| BETI stock issued for services (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
0
|
4
|
4
|
| BCPG stock issued for services (unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
0
|
0
|
0
|
20
|
20
|
| Balance (in shares) at Jun. 30, 2026 |
|
|
|
|
|
|
|
|
|
|
|
9,738,469
|
325,231,362
|
|
|
|
|
|
| Balance at Jun. 30, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
$ 217
|
$ 164,470
|
$ (166,333)
|
$ (206)
|
$ (878)
|
$ (2,730)
|